| [1] |
Slamon D J,Clark G M,Wong S G,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science,1987,235:177 -182.
|
| [2] |
Seshadri R,Firgaira FA,Horsfall D J,et al.Clinical significance of HER-2/neu oncogene amplification in primary breast cancer.The South Australia Breast Cancer Study Group. J Clin Oncol,1993,11:1936 -1942.
|
| [3] |
Bianco A R,DeLaurentis M,Carlomagno C,et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy:evidence of interaction between C-erbB-2 expression and tamoxifen efficacy/ /4th Annual ASCO Meeting. VA,Alexandria:ASCO Press Center,1998:373.
|
| [4] |
Ellis M J,Coop A,Singh B,et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.Cancer Res,2003,63:6523 -6531.
|
| [5] |
Muss H,Berry D,Thor A,et al.Lack of interaction of tamoxifen use and ERBb·2/neu (H) expression in CALGB8541:a randomized adjuvant trial of three diferent doses of CAF in node-positive breast cancer.Proc Am Soc Clin Oncol,1998,18:68.
|
| [6] |
Allied D C,Clark G M,Tandon A K, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the prnsence of in situ carcinoma.J Clin Oncol,1992,10:599 -605.
|
| [7] |
Tanner M,Isola J,Wiklund T,et al. Topoisomerase Ⅱalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthrax cycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:Scandinavian Breast Group Trial 9401.J Clin Oncol,2006,24:2428 -2436.
|
| [8] |
Burstein H J,Harris L N,Gelman R,et al.Preoperative tHERapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER-2 overexpressing stageⅡorⅢbreast cancer:a pilot study.J Clin Oncol,2003,21:46-53.
|
| [9] |
Buzdar A U,Ibrah im N K,F rancis D,et al.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy:results of a random ized trial in human epidermal growth factor receptor 22 positive operable breast cancer.J Clin Oncol,2005,23:3676 -3685.
|
| [10] |
Gianni L,Semiglazov V,Manikhas G M,et al. Neoadjuvant trastuzumab plus doxorubicin,paclitaxel and CMF in locally advanced breast cancer (NOAH trial):Feasibility,safety and antitumor effects/ /2007 Breast Cancer Symposium. VA,Alexandria:ASCO Press Center,2007:144.
|
| [11] |
Marty M,Cognetti F,Maraninchi D,et al.Randomized phase Ⅱtrial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as firstline treatment:the M77001 study group.J Clin Oncol,2005,23:4265 -4274.
|
| [12] |
Pegram M D,Pienkowski T,Northfelt D W,et al.Results of two open-label,multicenter phase Ⅱstudies of docetaxel,platinum salts, and trastuzumab in HER-2-positive advanced breast cancer.J Natl Cancer Inst,2004,96:759 -769.
|
| [13] |
Pegram M,Forbes J,Pienkowski T,et al. BCIRG 007:First overall survival analysis of randomized phase Ⅲ trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER-2 amplified metastatic breast cancer(MBC)/ /2007 ASCO Annual Meeting. VA,Alexandria:ASCO Press Center,2007:1008.
|
| [14] |
Morabito A, Longo R, Gattuso D, et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer.Oncol Rep,2006,16:393 -398.
|
| [15] |
Nahta R,Takahashi T,Ueno NT,et al. P27(kip1) downregulation is associated with trastuzumab resistance in breast cancer cells.Cancer Res,2004,64:3981 -3986.
|
| [16] |
Gelmon KA,Mackey J,Verma S,et al. Use of trastuzumab beyond disease progression:observations from a retrospective review of case histories Clin Breast Cancer,2004,5:52 -58.
|
| [17] |
Press M F,Finn R,DiLeo A, et al.Correlation of HER-2 gene amplification and immunohistochemistry (IHC) with clinical efficacy in women with metastatic breast cancer (MBC) treated with lapatinib/ /2007 Breast Cancer Symposium. VA,Alexandria:ASCO Press Center,2007:51.
|